Rare Kidney Disease Market Revenue to Cross US$ 12.1 million by 2035

Published: April 2024


According to a recently published report by Roots Analysis, rising need for drugs targeting rare kidney disease has enabled the researchers to focus on leveraging their expertise and capabilities to streamline the development processes and expedite the drug approvals for rare kidney diseases, driving the market of rare kidney diseases.

Rare Kidney Disease Industry Overview

The rare kidney disease market size anticipated to grow at a CAGR of 11% in the forecast period 2024-2035, reaching USD 12.1 billion by 2035.

With over 119 rare kidney disease therapies in various stages of clinical stage of development, and more than 210 clinical studies currently evaluating these therapies across various target indications; it is safe to say that rare kidney disease candidates have demonstrated tremendous potential with an aim to treat rare and complex diseases, including target disease indications for which no effective treatment is currently available. Ongoing studies aim to uncover the specific mechanisms underlining these therapies, paving the way for a more targeted and effective approach to harness their potential for medical purposes. Given the extensive research efforts in the rapidly evolving rare kidney disease landscape, developers bring expertise in navigating complex regulatory frameworks, optimizing study designs, and supporting seamless transition from preclinical to clinical success. The aforementioned factors are likely to present lucrative market growth opportunities for drug developers and this domain is anticipated to emerge within the pharmaceutical industry in the coming years.

Browse 140+ figures and 130+ market data tables spread across 250+ pages and detailed Table of Content on “Rare Kidney Disease Market by Target Disease Indications, Type of Molecule, Type of Biologics, Route of Administration, Type of Therapy, Key Geographical Regions, Leading Drug Developers and Sales Forecast: Industry Trends and Global Forecasts, Till 2035” here: https://www.rootsanalysis.com/reports/rare-kidney-diseases-market.html

Market Drivers

Several factors contribute to the growth of the rare kidney disease market. The expanding pipeline of rare kidney disease therapies, with over 21,630 patients enrolled for clinical trials evaluating rare kidney disease therapies across various developmental stages has propelled the market. This surge can be attributed to the significant rise in the incidence rate of rare kidney diseases worldwide. Consequently, this has led to the increase in the demand for more effective treatments and therapies for rare kidney diseases which has contributed to the growth of this domain. Further, To investigate the new pathophysiological pathways for the identification of biomarkers and increase the success rate of rare kidney disease drug development, various technologies are being integrated with the ability to probe the diseased organ directly, thereby contributing to the growth of this market.

Market Restraints

Despite several patients worldwide suffering from rare kidney diseases, research funding and healthcare policies often prioritize managing more common diseases affecting larger populations, neglecting the need for targeted approaches necessary to effectively treat such rare conditions. Moreover, physicians and patients lack awareness of rare kidney conditions, and due to the limited availability of data on rare kidney diseases there have been several gaps in innovative research, health care approaches, and policy actions to deal with shortcomings in research and clinical care dedicated to rare kidney diseases, further hindering the market growth.

Growth Factors

Despite several challenges, various growth factors continue to drive the rare kidney disease market. One of the notable factors is that several developers have expanded their pipeline portfolio, thereby expanding their capabilities. In addition, given the specialized nature of these rare conditions and the willingness of payers to reimburse for therapies addressing rare kidney diseases. Drug developers involved in the development of rare kidney disease drugs may have more flexibility in pricing such drugs. Moreover, collaborations among pharmaceutical companies, academic institutions, and research organizations to address unmet medical needs globally, are likely to drive considerable growth in the market.

Rare Kidney Disease Market Segments

Based on target disease indication, the market is segmented into Atypical Hemolytic Uremic Syndrome, Autosomal Dominant Polycystic Kidney Disease, Fabry Disease, Immunoglobulin A Nephropathy, Focal Segmental Glomerulosclerosis, Lupus Nephritis and Other Indications.

  • The Atypical Hemolytic Uremic Syndrome segment capture the largest revenue share of more than 35% in the rare kidney disease market, in 2024.
  • The Focal Segmental Glomerulosclerosis segment is anticipated to be the fastest growing segments in this industry, with annualized rate of over 42%, during the forecast period.

Based on the type of molecule, the market is segmented into Small Molecules and Biologics.

  • The small molecules segment capture the largest revenue share of close to 55% in the rare kidney disease market, in 2024.
  • The small molecules segment is anticipated to witness the highest market growth rate of around 12%, annually during the forecast period.

Based on type of biologics, the market is segmented into Monoclonal Antibodies and Proteins.

  • The monoclonal antibodies segment capture the largest revenue share of close to 95% in the rare kidney disease market, in 2024.
  • The proteins segment is anticipated to witness the highest market growth rate of more than 25%, annually during the forecast period.

Based on route of administration, the market is segmented into Oral, Intravenous, Subcutaneous, and Other Routes of Administration.

  • The oral segment capture the largest revenue share of close to 55% in the rare kidney disease market, in 2024.
  • The subcutaneous segment is anticipated to witness the highest market growth rate of around 70%, annually during the forecast period.

Based on type of therapy, the market is segmented into Monotherapy and Combination Therapy.

  • The monotherapy segment capture the largest revenue share of 100% in the rare kidney disease market, in 2024.
  • The combination therapy segment is anticipated to witness the highest market growth rate of around 75%, annually during the forecast period.

Based on the Regional Insights, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World

  • North America dominated the rare kidney disease market and accounted for the largest revenue share of 50% in 2024.
  • In Asia-Pacific, the rare kidney disease market is anticipated to demonstrate lucrative growth during the forecast period.

Key Companies Profiled

The rare kidney disease market report also includes detailed profiles of key players (listed below) that are involved in development of rare kidney disease therapies:

  • Alexion Pharmaceuticals 
  • Chinook Therapeutics 
  • Horizon Therapeutics 
  • Jiangsu Hengrui Pharmaceuticals
  • Novartis
  • Omeros
  • Roche
  • Sanofi
  • Travere Therapeutics
  • ZyVersa Therapeutics
  • Advicenne
  • Apellis Pharmaceuticals
  • argenx
  • Astellas Pharma
  • Boehringer Ingelheim
  • Calliditas Therapeutics
  • GSK
  • Mallinckrodt Pharmaceuticals
  • Synlogic
  • Takeda

You Can Download Free Sample PDF Copy of This Report At:
https://www.rootsanalysis.com/reports/rare-kidney-diseases-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com

MEDIA CITATIONS

  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry